Journal of Breast Cancer

  • 제21권4호
  • /
  • Pages.468-470
  • /
  • 2018
  • /
  • 1738-6756(pISSN)
  • /
  • 2092-9900(eISSN)
한국유방암학회 (Korean Breast Cancer Society)
권호 표지

The Open Issues Regarding Cyclin-Dependent Kinase 4/6 Inhibitors in the Management of Advanced Breast Cancer

  • 투고 : 2018.09.25
  • 심사 : 2018.10.10
  • 발행 : 2018.12.31
⟨ 이전 논문 다음 논문 ⟩

초록

키워드

참고문헌

  1. Choo JR, Lee SC. CDK4-6 inhibitors in breast cancer: current status and future development. Expert Opin Drug Metab Toxicol 2018;14:1123-38.
  2. Clinical practice guidelines in oncology: breast cancer. version 4.2017. National Comprehensive Cancer Network. http://www.nccn.org/. Accessed February 7th, 2018.
  3. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, Andre F, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol 2018;29:1634-57. https://doi.org/10.1093/annonc/mdy192
  4. DeMichele A, Chodosh LA. “Braking” the cycle of resistance in endocrine therapy for breast cancer. Clin Cancer Res 2015;21:4999-5001. https://doi.org/10.1158/1078-0432.CCR-15-1146
  5. Lenihan C, Bouchekioua-Bouzaghou K, Abdulghani R, Chupin J, Shia A, Schmid P. CDK4/6 inhibitor resistant ER-positive cells remain dependent on estrogen signalling and retain sensitivity to endocrine therapy. 40th Annual San Antonio Breast Cancer Symposium. 2016. Abstract #P3-03-12.
  6. Kalinsky K, Mundi PS, Chiuzan C, Accordino MK, Trivedi MS, Sparano JA, et al. A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer. J Clin Oncol 2017;35(15 Suppl):TPS1112. https://doi.org/10.1200/JCO.2017.35.15_suppl.TPS1112
  7. Bardia A, Hurvitz S, Yardley DA, Zelnak A, DeMichele A, Clark AS, et al. TRINITI-1: Ribociclib + everolimus (EVE) + exemestane (EXE) triplet combination in men or postmenopausal women with HR+, HER2- advanced breast cancer (ABC) following progression on a cyclin-dependent kinase (CDK) 4/6 inhibitor. Cancer Res 2017;77(4 Suppl):OT2-01-05.
  8. Zhang J, Xu K, Liu P, Geng Y, Wang B, Gan W, et al. Inhibition of Rb phosphorylation leads to mTORC2-mediated activation of Akt. Mol Cell 2016;62:929-42. https://doi.org/10.1016/j.molcel.2016.04.023
  9. Finn RS, Crown JP, Ettl J, Schmidt M, Bondarenko IM, Lang I, et al. Efficacy and safety of palbociclib in combination with letrozole as firstline treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res 2016;18:67. https://doi.org/10.1186/s13058-016-0721-5
  10. Cardoso F, Villanueva C, Royce M, Cruz F, Debled M, Hegg R, et al. Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC): first- and second-line data from the BOLERO-4 study. J Clin Oncol 2017;35(15 Suppl):1010. https://doi.org/10.1200/JCO.2017.35.15_suppl.1010
  11. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011;11:558-72. https://doi.org/10.1038/nrc3090
  12. Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell 2016;29:255-69. https://doi.org/10.1016/j.ccell.2016.02.006